The majority of pancreatic cancers (from 75 to 95%) harbor a KRAS mutation at codon 129 and a significant difference in survival was observed in patients with detectable or undetectable KRAS mutations (mutKRAS) in circulating free tumor DNA (cftDNA)10. The gene discussed is KRAS; the disease is neoplasm.